Hepatocellular carcinoma (Q57756376)

Europe PubMed Central

title

Hepatocellular carcinoma (English)

0 references

1

Josep M. Llovet

0 references

Gregory J Gores

7

object named as

Gregory Gores

0 references

author name string

Jessica Zucman-Rossi

2

0 references

Eli Pikarsky

3

0 references

Bruno Sangro

4

0 references

Myron Schwartz

5

0 references

Morris Sherman

Nature Reviews Disease Primers

6

0 references

publication date

14 April 2016

0 references

published in

0 references

volume

2

0 references

page(s)

16018

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrdp.2016.18

0 references

cites work

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Functional and genetic deconstruction of the cellular origin in liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Toward understanding and exploiting tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The role of telomeres in stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Telomerase gene mutations are associated with cirrhosis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Constitutional telomerase mutations are genetic risk factors for cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatitis C virus-induced hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Mechanisms of HBV-related hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

NRF2 and cancer: the good, the bad and the importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The liver as a lymphoid organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Antigen-presenting cell function in the tolerogenic liver environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radical causes of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Pathobiology of liver fibrosis: a translational success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The impact of hepatitis C burden: an evidence-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Therapy. Statins and liver disease: from concern to 'wonder' drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Frequency of and predictive factors for vascular invasion after radiofrequency ablation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Liver cancer: Approaching a personalized care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Resection and liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Second hepatic resection for recurrent hepatocellular cancer: a Western experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Image-guided ablation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Research reporting standards for radioembolization of hepatic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Transarterial chemoembolization and radioembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Radioembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Targeting the HGF/c-MET pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-lif

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Can we safely target the WNT pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

The role of hepatic resection in the treatment of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Biological and therapeutic impact of intratumor heterogeneity in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Liquid biopsy: monitoring cancer-genetics in the blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Optimization of imaging diagnosis of 1–2cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Laparoscopic liver resection: A new paradigm in the management of hepatocellular carcinoma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four -Fetoprotein Peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Intratumor molecular and phenotypic diversity in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18

Non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.18